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CONDENSED ABSTRACT: Celecoxib inhibits meningioma growth in vivo at plasma 
levels achievable in humans. COX-2 inhibitors may have a role in treatment of 
recurrent meningiomas.
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Background: Treatments for recurrent meningiomas are limited. We previously 
demonstrated universal expression of COX-2 in meningiomas and dose-dependent 
growth inhibition in vitro with celecoxib, a COX-2 inhibitor. We therefore tested the 
effects of celecoxib on meningioma growth in a mouse xenograft model.
Methods: Meningioma cell lines (lOMM-Lee, CH157-MN, WHO grade I primary cultured 
tumor) were transplanted into flanks of nude mice fed mouse chow with celecoxib at 
varying concentrations (0, 500, 1000, 1500ppm) ad libitum. Tumors were measured 
biweekly and processed for MIB-1, Factor VIII, COX-2, and VEGF, and assayed with 
TUNEL.
Results: Celecoxib reduced growth of mean tumor volume by 66% (P<0.05), 25% 
(P>0.05), and 65% (P<0.05) compared with untreated controls in lOMM-Lee, CH157- 
MN, and benign tumors, respectively. lOMM-Lee tumors removed from celecoxib 
treatment regained a growth rate similar to the control. Blood vessel density decreased 
and apoptotic cells increased in treated flank tumors. Diminished COX-2 expression and 
VEGF were observed in treated lOMM-Lee tumors. Mean plasma celecoxib levels were 
845, 1540, and 2869ng/mL, for low-, medium-, and high-dose celecoxib, respectively.
Conclusions: Celecoxib inhibits meningioma growth in wVoat plasma levels achievable 
in humans. Celecoxib-treated tumors were less vascular with increased apoptosis.
University of Utah Institutional Repository
Author Manuscript
Ragel et al. 3
UU 
IR Author Manuscript 
UU 
IR Author Manuscript
lOMM-Lee tumors treated with celecoxib showed decreased COX-2 and VEGF 
expression. COX-2 inhibitors may have a role in treatment of recurrent meningiomas.
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Meningiomas account for ~20% of all primary intracranial tumors, making them 
the second most common symptomatic adult central nervous system tumor.
Meningioma progression or recurrence may occur because of aggressive biology or 
unresectable location.13 Recurrence rates for benign meningiomas five years after 
complete removal are only 2-3%, whereas recurrence rates for atypical and anaplastic 
meningiomas are 38-50% and 33-78%, respectively 4 5 Treatment options for recurrent 
meningiomas are limited:6 7 Radiation therapy is limited by side effects and tumor size, 
and systemic therapies have largely been disappointing.7 9 Therefore, exploration of 
new treatment options is necessary.
The results of several head trauma epidemiologic studies have implicated the 
inflammatory process in meningoma pathogenesis.10 Cyclooxygenase-2 (COX-2) is an 
inducible inflammatory response enzyme that is up-regulated in animal head trauma 
models.11 Cyclooxygenase is the rate-limiting enzyme in the synthesis of prostaglandins 
from arachidonic acid.12 Because prostaglandins are involved in various biologic 
activities, such as angiogenesis, increased cell proliferation, and suppression of 
apoptosis, interruption of this pathway may provide a therapeutic option in the treatment 
of recurrent meningiomas.
Overexpression of COX-2 has been closely linked to the tumorigenesis of colon, 
lung, and breast cancers.12 13 A growing body of literature supports the use of 
nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors in the treatment of 
an ever-widening number of cancers.14 Previously, we demonstrated that COX-2 is 
universally expressed in meningiomas and that celecoxib, a selective COX-2 inhibitor,
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inhibits meningioma growth in vitro, with evidence of apoptosis.15 In this study, we 




A meningioma surgical specimen was obtained under Institutional Review Board- 
approved protocol and processed for cell culture. The tumor was graded as a WHO 
grade I meningioma,2 which, for the purposes of this paper, we will describe as a 
primary cultured “benign meningioma.” This tumor specimen was grown as monolayer 
culture as described previously. Briefly, specimen was taken immediately from the 
operating room, digested in collagenase, and placed in Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma) supplemented with 10% fetal calf serum, L-glutamine (2pM), 
penicillin (50IU/ml_), and streptomycin (50mg/mL). Cultured cells were maintained at 
37°C in 7.5%C02.
The human meningioma immortal cell lines lOMM-Lee and CH157-MN were also 
grown in DMEM supplemented with 10% fetal calf serum, L-glutamine (2pM), penicillin 
(50IU/mL), and streptomycin (50mg/mL) at 37°C in 7.5%C02.16 17 The lOMM-Lee and 
CH157-MN cell lines were kind gifts from Dr. Ian McCutcheon (University of Texas,
M.D. Anderson Cancer Center, Houston, Texas) and Dr. Yancey Gillespie (University of 
Alabama School of Medicine, Birmingham), respectively.16 17
In vitro assays for COX-2 function
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To determine the effects of celecoxib treatment on the COX-2 enzyme, we 
analyzed lOMM-Lee cells grown in cell culture for COX-2 activity as well as cellular 
levels of prostaglandin E2 (PGE2). lOMM-Lee cells were plated in T-175 flasks and 
allowed to grow to 75% confluence. Flasks were treated with vehicle control 
(0.1%DMSO) or 1.00mM celecoxib, as previously described.15 Cells were harvested 
after 24h of treatment and protein was isolated. A total of four samples were processed 
for each treatment group.
Briefly, cells were rinsed with ice-cold Dulbecco’s phosphate buffered saline, 
scraped from the culture dish, pelleted at 1,000g for 10min at 4°C, resuspended in 
250|jL of ice-cold buffer (0.1M Tris-HCI [pH7.8], containing 1mM 
ethylenediaminetetraacetic acid), and sonicated for 10sec three times. Cellular debris 
was pelleted by centrifugation at 10,000g at 4°C for 15min. The supernatant (nuclear 
and cytoplasmic) was removed and stored at -80°C until use. Samples were processed 
in triplicate for COX-2 activity (COX Activity Assay, Cayman Chemical Company, Ann 
Arbor, Ml) and PGE2 enzyme immunoassay (Prostaglandin E2 EIA Kit-Monoclonal, 
Cayman Chemical Company) per the manufacturer’s protocol.
Meningioma mouse xenograft flank model
All animal experiments were approved by the Animal Care and Use Committee of 
The University of Utah. Subcutaneous meningioma flank tumors were implanted as 
described previously.18 Briefly, cells were grown to ~80% confluence in T-175 flasks. All 
steps were carried out on ice. The cells were rinsed with PBS, trypsinized, counted 
using a bright-line hemocytometer, pelleted at 1000rpm for 5min at 4°C, and
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resuspended in media (lOMM-Lee and CH157-MN cell lines) or Matrigel (BD 
Biosciences, San Diego, CA) (primary meningioma cell line). Desired cell counts were 
500,000 cells per mouse flank for the immortal cell lines and 5,000,000 per mouse flank 
for the primary meningioma cell line. A total volume of 0.10-0.15mL was injected 
subcutaneously into the flanks of immunodeficient mice (CD1, Charles River 
Laboratories, Wilmington, MA) using a tuberculin syringe and 25-gauge needle. Three- 
week-old mice were used for the dose-response experiments, whereas three-month-old 
mice were used for the prophylactic treatment experiments, as described below.
First, we performed dose-response experiments using 3-week-old mice and the 
lOMM-Lee cell line (control (n=20); low-dose (n= 10), medium-dose (n=10), high-dose 
(r?=15) celecoxib). Second, we repeated the high-celecoxib dosing regime with 3-week- 
old mice and both the CH157-MN cell line (control (n= 10), high-dose celecoxib (n=5)) 
and the benign cell line (control (n=5), high-dose celecoxib (n=5)). Mice were sacrificed 
with a lethal intraperitoneal injection of pentobarbital. Flank tumors were excised, cut 
into blocks, and placed in 10% formalin for paraffin blocks or snap frozen in liquid 
nitrogen. Cardiac puncture was performed after euthanasia to obtain blood for celecoxib 
serum analysis.
Treatment with celecoxib
Celecoxib (G.D. Searle LLC, Chicago, IL) was included in mouse chow (Rodent 
Diet 8656, Harlan Teklad, Madison, Wl) at 500 (low celecoxib), 1000 (medium), and 
1500ppm (high). Tumors were allowed to grow for 10-14d before the initiation of 
treatment to allow the Matrigel or medium to resorb completely. The start of tumor
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measurements was correlated with the initiation of the treatments. Control mice were 
fed regular mouse chow ad libitum. Treated mice were fed celecoxib mouse chow ad 
libitum. Mice in the prophylactic treatment groups were fed low-, medium-, or high-dose 
celecoxib for 6 weeks prior to subcutaneous flank injections and until sacrifice or the 
end of treatment.
Analysis of celecoxib serum levels
Following the sacrifice of the mice, whole blood was aspirated via cardiac 
puncture, placed into plasma separator tubes, and spun at 1,000rcf for 5min. The 
isolated plasma was placed into cryogenic tubes and stored at -80°C. Serum samples 
were shipped on dry ice to National Medical Services (Willow Grove, PA) for celecoxib 
serum analysis by high-performance liquid spectroscopy.
Immunohistochemistry
Immunohistochemistry analysis on formalin-fixed, paraffin-embedded 
meningoma mouse xenograft tumors was accomplished for MIB-1, Factor VIII, VEGF, 
and COX-2. Slides were cut at 4 microns, then melted at 55-60°C for 30min, 
deparaffinized in xylene for 5min, and rehydrated in graded alcohols (100%x2, 95%x2, 
70%x1) for 1min each. The following steps were performed on the Ventana ES 
(Ventana Medical Systems, Tucson, AZ) at40°C. Heat-induced epitope retrieval was 
accomplished by applying citrate buffer (pH6.0) in a microwave oven for 15min at half 
power and allowing it to cool for 15min for tissue stained for Factor VIII, VEGF, and 
COX-2. For the MIB-1 immunohistochemical staining, heat-induced epitope retrieval
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was accomplished by applying citrate buffer (pH6.0) in an electric pressure cooker for 
3min and allowing it to cool for 27min. The primary antibodies [Ki-67 (1:100, mouse 
monoclonal Ab, Clone MIB-1, Dako Cytomation, Carpinteria, CA), Factor VIII (1:1600, 
rabbit polyclonal Ab, Dako Cytomation), COX-2 (1:200, rabbit polyclonal, Lab Vision, 
Fremont, CA), or VEGF (1:200, mouse monoclonal, Dako Cytomation)] were applied for 
32min followed by the appropriate secondary antibody [Mouse primary antibody: Mouse 
Fab (1:200, Mouse IgG, Dako Cytomation); rabbit primary antibody: Goat anti­
mouse/anti-rabbit (1:300, Rabbit Fab, Dako Cytomation)] for 8min. Detection was done 
using the IView DAB detection kit (Ventana) and the counterstain was done with 
Hematoxylin (Ventana) for 4min. Slides were then dehydrated through graded alcohols 
(70%x1, 95%x2, 100%x2) for 30 seconds each, dipped in 4 changes of xylene, and 
covered with a coverslip. Positive controls consisted of pancreas tumor, normal tonsil, 
colon cancer, and normal colon for MIB-1, Factor VIII, COX-2, and VEGF, respectively. 
Negative controls were accomplished by running the above positive control tissue 
without the primary antibody.
Apoptosis assay
The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling 
(TUNEL) technique was used to label the fragmented DNA of apoptotic cells. Formalin- 
fixed, paraffin-embedded mouse meningoma xenograft tumors were processed as 
recommended by the manufacturer (TUNEL Assay, Promega, Madison, Wl), staining 
the fragmented DNA of apoptotic cells brown.
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Immunohistochemical and apoptosis analysis
Analysis of MIB-1 staining was performed by taking 6 random pictures per slide 
at 400x (10x ocular x 40x objective) using an Olympus Microfire camera. The images 
were analyzed using the Image-Pro Plus 5.0 graphic analysis program (Media 
Cybernetics, Silver Spring, MD). Results were reported as number of MIB-1 cells 
positive per 40x high-powered field (hpf) and represent the mean (±standard deviation) 
of 6 random fields. Three flank tumors were analyzed per treatment group, one slide per 
tumor.
Microvascular density analysis was achieved by scoring Factor VIIl-stained 
slides, counting the number blood vessels positive in three 200x fields (10x ocular x 20x 
objective). Microscope fields were chosen based on the three fields with the maximal 
number of blood vessel stained (i.e., Factor VIII “hot-spots”), as described previously. 
Three flank tumors were analyzed per treatment group, one slide per tumor.
Immunohistochemical analysis for COX-2 and VEGF was accomplished by 
scoring 6 random fields per slide at 200x (10x ocular x 20x objective) for the percentage 
of cells stained and staining intensity. Areas of tumor necrosis and edge artifact were 
avoided. The percentage of cells stained was estimated to be 0%, 25%, 50%, 75%, or 
100%. The intensity score was measured using a numerical scale (0 =no expression, 1 + 
=weak expression, 2+ =moderate expression, 3+ =strong expression.) A weight index 
was calculated [Wl=% positive staining (>0) x intensity score]. Three flank tumors were 
analyzed per treatment group, one slide per tumor.
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TUNEL staining for apoptosis was analyzed by counting the number of positively 
stained cells in 6 random fields per slide at 400x (10x ocular x 40x objective), avoiding 
areas of necrosis. Three flank tumors were analyzed per treatment group, one slide per 
tumor.
Statistical analysis
In vitro data and immunohistochemical staining data (MIB-1, Factor 8, and 
TUNEL) were analyzed with the Student’s t-test (unpaired, two-tailed t-test with 
confidence intervals set to 95%), whereas tumor growth curves and weighted 
immunohistochemical staining data (COX-2 and VEGF) were analyzed with one-way 
analysis of variance (one-way ANOVA, Tukey post-test with confidence intervals set to 
95%) to compare control and treated groups, with statistical significance set at P<0.05. 
Survival curves were analyzed with the %2 test, with statistical significance set at a 
P<0.05. Statistics were analyzed using the GraphPad Prism 4.0 (San Diego, CA) 
statistical program.
RESULTS
Celecoxib inhibits COX-2 activity and decreases PGE2 concentrations in vitro
The lOMM-Lee cell line was grown in culture, treated with 1.0mM celecoxib for 
24h, and processed for COX-2 function to include the COX-2 activity assay and PGE2 
metabolite levels. Celecoxib completely inhibited mean (±SD) COX-2 activity in vitro 
with an overall reduction of 100% (2.9±1.2U/mL vs. -0.1±0.5U/mL; t-test P=0.004)
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(Figure 1). Correspondingly, cellular PGE2 levels fell by 51% (50.9±21.5ng/mL vs. 
24.9.1±10.3ng/mL; t-test P=0.003) (Fig. 1).
Meningioma flank tumor characteristics
The lOMM-Lee immortal cell line was originally obtained from a 61-year-old man 
with an interosseous meningioma, WHO grade 3, in 1990.16 The CH157-MN immortal 
cell line was originally obtained from a 55-year-old woman.17 The WHO grade I tumor 
was a convexity, transitional meningoma, obtained from a 55-year-old man. All three 
meningiomas underwent Giemsa-band karyotype showing chromosomal abnormalities 
consistent with meningiomas (e.g., loss of chromosomes 1 and 22, as well as addition 
of chromosomes 1, 9q, 12q, 18, 20) (data not shown)2 15 19 Histologically, flank tumors 
derived from lOMM-Lee and CH157-MN cell lines exhibited sheeting cytoarchitecture 
composed of large pleomorphic tumor cells. The benign cell line showed a 
cytoarchitecture vaguely resembling the original operative transitional meningioma 
subtype. Macroscopically, all three of these tumors exhibited a necrotic core with a 
peripheral ring of live tumor. Immunohistochemically, the lOMM-Lee, CH157-MN, and 
benign meningoma flank tumors were vimentin positive, epithelial membrane antigen 
positive, and glial fibrillary acid protein negative (data not shown). Transmission electron 
microscopy of the lOMM-Lee and CH157-MN flank tumors exhibited ultrastructural 
features consistent with meningiomas (e.g., intercellular junctions) (data not shown).20 
These features (i.e., karyotypic abnormalities, immunohistochemistry, and ultrastructural 
features) are typical of meningiomas.19'21




IR Author Manuscript 
UU 
IR Author Manuscript
Effect of celecoxib treatment on meningioma growth in vivo
The results of dose-response experiments comparing the growth rate of IOMM- 
Lee tumors treated with low-, medium-, and high-dose celecoxib showed a trend toward 
a dose-dependent growth inhibition response (Fig. 2A). No statistically significant 
difference in tumor growth inhibition was found between the control and low- and 
medium-dose celecoxib treatment groups (ANOVA, P>0.05), whereas the high-dose 
group showed statistically significant growth inhibition by day 43 (ANOVA, P<0.01). 
Doubling time for the lOMM-Lee tumors in the control and high-dose treatment groups 
was ~2 and ~4 weeks, respectively. High-dose celecoxib treatment reduced the mean 
(±SD) tumor volume over control by 66% at 6 weeks (2821 ±1907mm3 vs. 948±728mm3, 
ANOVA, P<0.01).
Based on the results from the lOMM-Lee dose-response experiments, we 
repeated the high-dose celecoxib treatment regime in vivo with the CH157-MN line and 
a benign meningoma mouse xenograft. The CH157-MN tumors in the control and high- 
dose celecoxib treatment groups doubled in ~6 and ~7d, respectively (Fig. 2B). 
Treatment reduced mean tumor volume by 25% by 6 weeks (3196±257mm3 vs.
2405±1944mm3, ANOVA, P>0.05) The benign meningioma in the control and high-dose 
treatment groups doubled in ~2 weeks and ~5 weeks, respectively (Fig. 2C). Treatment 
reduced mean tumor volume by 65% by 5 weeks (5588±3405mm3 vs. 1966±1685mm3, 
ANOVA, P<0.05). Statistically significant differences in tumor growth inhibition were 
noted between control and high-dose celecoxib treatment groups for the lOMM-Lee and 
benign meningioma flank tumors.
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The lOMM-Lee, CH157-MN, and benign groups each showed 100% tumor 
induction (55/55, 15/15, and 10/10, respectively). The lOMM-Lee control group had one 
tumor that regressed in size (5%, 1/20).
Survival curves showed no statistically significant difference in the death rate 
between control and treated groups (%2test, P>0.05, data not shown). Three of 20 
control lOMM-Lee mice died, whereas none (0/10) in the low-dose group, none (0/10) in 
the medium-dose group, and two (2/15) mice in the high-dose celecoxib group died by 
day 43. No animals died in the CH157-MN tumor groups. One animal in the control 
benign meningioma flank tumor group died, and none (0/5) of the high-dose celecoxib 
group died by day 35.
Celecoxib plasma levels
Celecoxib serum levels obtained on sacrificed animals fed low-, medium-, and 
high-dose celecoxib mouse chow ad libitum for a minimum of 35d (i.e., drug levels 
reflect steady state) showed mean celecoxib plasma values (±SD) of 845(±267) ng/mL, 
1540(±493) ng/ml_, and 2869(±828) ng/ml_, respectively (Fig. 3).
Immunohistochemical staining and TUNEL results
Immunohistochemistry was performed to analyze proliferative rates (MIB-1), 
microvascular density (Factor VIII), and COX-2 and VEGF expression in flank tumors 
treated with celecoxib. Immunohistochemical staining for the MIB-1 cell proliferative 
marker showed a slight increase in the mean number of cells positive in the lOMM-Lee 
flank tumors treated with high-dose celecoxib by 6% (211±75 vs. 223±64, P=0.627) and
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a significant increase of 14% (190±24 vs. 217±23, P=0.005) in the CH157-MN tumors 
(Fig. 4A). Conversely, the benign flank tumors treated with high-dose celecoxib showed 
a significant decrease in the mean number of MIB-1 positive cells by 21% (233±60 vs. 
184±61, t-test, P=0.024, Fig. 4A,B).
Factor VIII microvascular density analysis showed a decrease in microvascular 
density of 22% (t-test, P=0.278), 77% (t-test, P=0.009), and 37% (t-test, P=0.015) in the 
lOMM-Lee, CH157-MN, and benign flank tumors treated with high-dose celecoxib 
compared with the controls. Mean microvascular densities (±SD) per 20x hpf for the 
lOMM-Lee, CH157-MN, and benign flank tumors for control versus high-dose celecoxib 
treatment were 4.9(±2.8) versus 3.8(±0.8), 5.2(±1.2) versus 1,2(±0.4), and 5.1 (±1.4) 
versus 3.2(±1.5), respectively (Fig. 4B).
The TUNEL apoptosis stain showed that treated groups had 36% (t-test, 
P=0.516), 152% (t-test, P=0.002), and 288% (t-test, P= 0.022) more cells undergoing 
apoptosis for lOMM-Lee, CH157-MN, and benign flank tumors treated with high-dose 
celecoxib than did the control groups. Mean TUNEL positive cells (±SD) per 40x hpf for 
the lOMM-Lee, CH157-MN, and benign flank tumors for control versus high-celecoxib 
treatment were 1.4(±1.8) versus 1.9(±2.0), 1.3(±1.5) versus 3.2(±1.9), and 0.8(±0.9) 
versus 3.1 (±3.4), respectively (Fig. 4C).
Immunohistochemical staining for COX-2 and VEGF accomplished on lOMM-Lee 
xenograft tumors showed decreased staining scores with increasing celecoxib dose 
(Fig. 5A-C). Statistical significance was achieved for both COX-2 and VEGF at high- 
celecoxib dosing (ANOVA, F<0.001).








The COX-2 enzyme is ubiquitously expressed in meningioma cells and also is 
present in endothelial cells, macrophages, and stromal tissues.15 22 24 Up-regulation of 
COX-2 contributes to tumor growth in cancer models by increasing angiogenesis and 
cellular proliferation, as well as decreasing apoptosis.14 22 25 Celecoxib, a selective 
COX-2 inhibitor, was chosen because of its FDA approval and has been shown to 
decrease cancer growth in vitro and in vivo by both COX-2-dependent and COX-2- 
independent mechanisms, making it difficult to ascertain whether drug effect is due to 
direct COX-2 inhibition.26 27 Regardless of the mechanism, we have demonstrated that 
celecoxib decreases meningioma growth in vivo with evidence of decreased 
microvascular density, increased apoptosis, and decreased COX-2 and VEGF 
expression. Celecoxib mouse serum levels for the low- and medium-dose regimes were 
well within reported ranges, whereas the high-dose regime, although achievable, is 
unrealistic in humans.
First, we showed that celecoxib eliminates COX-2 activity in vitro, corresponding 
with a 51% reduction in PGE2 levels. Our previous in vitro work showed growth 
inhibition and apoptosis at similar celecoxib doses; however, it was unclear whether 
these findings were due to direct-COX-2 inhibition and subsequent reduction in 
prostaglandins or via other mechanisms.15 These results fit with the extensive in vitro 
data on numerous cell lines showing growth inhibition by selective COX-2 inhibitors.15 
23 28 Specifically, another study on other brain tumors with the COX-2 inhibitor NS-398 
showed inhibition of cell proliferation and migration of the glioma cell lines U-87MG and 
U-251MG.15,29
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We demonstrated a statistically significant decrease in meningioma mouse flank 
tumor sizes with high-dose celecoxib treatment in two of three cell lines, with a final 
mean tumor volume reduction between 25 and 66%. A trend toward a dose-dependent 
response was seen in one cell line grown in mice flanks, but it did not reach statistical 
significance for the low- or medium-dose celecoxib groups. Prophylactically treating 
mice with high-dose celecoxib for 6 weeks before induction of lOMM-Lee xenograft 
tumors resulted in decreased tumor induction rates compared to control, low-, and 
medium- dose groups (80% vs. 100%) (data not shown). Furthermore, removal of drug 
resulted in the return of tumor growth to baseline tumor growth rates, suggesting a 
tumor growth-suppressive of remaining viable cells (data not shown). These findings 
agree with those of other in vivo solid tumor studies (e.g., colorectal, prostate, lung, 
squamous cell carcinoma, breast) showing decreased tumor size with celecoxib 
treatment.30"36
Studies consistently show that selective COX-2 inhibitors reduce angiogenesis, 
probably via direct inhibition of the COX-2 enzyme.22'25 COX-2 has been shown to 
regulate angiogenesis primarily through PGE2, which is a key regulator in stimulating 
VEGF expression.24,25,37,38 Furthermore, several in vitro studies show that COX-2 
inhibitors down-regulate COX-2 expression.39 40 We verify these findings by showing 
that celecoxib reduced microvascular density in meningioma flank tumors by 23-78%. 
Furthermore, we provide evidence that COX-2 expression is diminished in celecoxib- 
treated meningioma flank tumors. Finally, we observe that VEGF expression is 
diminished, suggesting that celecoxib ultimately inhibits microvascular proliferation by 
inhibiting VEGF stimulation. Liu et al. showed that selective COX-2 inhibition
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suppressed tumor growth through a down-regulation of a VEGF-mediated tumor 
angiogenesis.24 Taken together, these results indicate that selective COX-2 inhibitors 
probably mediate their antiangiogenic effects via direct inhibition of the COX-2 enzyme 
(i.e., COX-2-dependent effect). Although we are unclear whether the antiangiogenic 
effects in this study are due to direct COX-2 inhibition, we provide evidence to support 
that this is the case.
Selective COX-2 inhibition has been shown to promote apoptosis in numerous 
cell lines in vivo and in vitro22,27■38,41 ■42 In this study, we have shown that celecoxib 
increases the number of cells undergoing programmed cell death by 36-288%.
Although the specific antiapoptotic mechanism(s) remain unclear, proposed 
mechanisms include modulation of the BAX-to-bcl-2 ratio and activation of caspase 
pathways.13,41,42 Previous in vitro work accomplished in our laboratory has shown no 
significant change in BAX or bcl-2 expression by Western blot analysis.15 Thus, it 
appears that modulation of the BAX-to-bcl-2 ratio is not a factor in driving meningoma 
apoptosis in vitro, although we have not specifically studied this in vivo.
Celecoxib treatment of flank meningiomas resulted in slight increases in MIB-1 
staining of the immortal meningoma cell lines (lOMM-Lee and CH157-MN). Conversely, 
flank tumors induced by the benign cell line showed a decrease in the number of cells 
undergoing cell division. This corresponds with the mixed results reported by others.24
29 36 For example, the COX-2 inhibitor NS-398 inhibits cell proliferation and migration of 
the glioma cell lines U-87MG and U-251MG in vitro29 whereas others have shown no 
change in cell proliferation with selective COX-2 inhibition.24 36 Interestingly, because 
the MIB-1 antibody recognizes the Ki-67 nuclear antigen during G1, S, G2, and M
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phases of the cell cycle, treatment with drugs that halt cells in G1 or the G1-S transition 
(beyond GO but before S phase) can cause a paradoxical increase in labeling while still 
arresting cell growth.43 This may explain our findings of increased Ki-67 labeling in the 
immortal cell lines flank tumors.
The recommended dose for celecoxib in the treatment of rheumatoid arthritis, 
osteoarthritis, and familial adenomatous polyposis ranges from 200 to 800mg a day, 
and for clinical trials doses up to 800mg a day have been reported. The plasma half-life 
of celecoxib is 13h, with steady state reached at 5d. Peak plasma levels of 
approximately 800ng/mL (~0.8|jg/mL) have been observed after single 200-mg doses in 
healthy, fasting subjects.44 Peak plasma levels of 1234|jg/L (~1.2|jg/mL) and 1160|jg/L 
(~1.2|jg/mL) have been observed an average of 3h after 300-mg single dose (mean) 
and at steady state, respectively, in 11 pediatric patients ages 6 to 15 being treated for 
solid tumors 45 Frank et al. analyzed 35 adults taking celecoxib 400mg daily and 
reported a plasma concentration steady state of 600.61 ng/mL (~0.6jjg/mL) at 6 
weeks.46 Our in vivo celecoxib inclusion diets ranged from 500 to 1500ppm with mean 
plasma levels of 845ng/mL (~0.85jjg/mL), 1540ng/ml_ (~1.4ng/ml_), and 2869ng/mL 
(~2.9ng/ml_) for the low-, medium- and high-dose celecoxib doses, respectively. 
Therefore, our low- and medium-dose celecoxib diets yield plasma levels within 
reported human ranges. Plasma levels of the high-dose celecoxib diet, although 
achievable in humans, would require ingestion of roughly 3 grams of celecoxib daily, 
which is not realistic (Pfizer, personal communication). Unlike other central nervous 
system tumors (e.g., astrocytomas) meningiomas derive their blood supply primarily 
from extracranial blood vessels, thus they are located outside the blood-brain barrier.
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Therefore, intratumor drug concentrations from systemic therapies should mimic serum 
levels to a greater extent.
Celecoxib significantly inhibits meningioma growth in vivo at high plasma levels 
in this model. Overall, celecoxib-treated tumors were less vascular and had increased 
apoptosis than the control. lOMM-Lee tumors treated with celecoxib showed decreased 
COX-2 and VEGF expression. Interestingly, the tumor lines used in this study were 
highly aggressive, with areas of necrosis noted on histologic analysis. These findings 
are consistent with anaplastic meningiomas, perhaps making these findings more 
applicable to higher-grade tumors. COX-2 inhibitors may have a role in the treatment of 
recurrent meningiomas.
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Figure 1: Graphs of COX-2 activity and PGE2 enzyme immunoassay in lOMM-Lee cells 
treated with 1 .OmM celecoxib in vitro for 24h. Error bars represent four samples per 
group analyzed in triplicate. A. COX-2 activity was completely suppressed with a 
decrease of 100% in lOMM-Lee cells treated with 1 .OmM celecoxib for 24h (t-test, 
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Figure 2: Celecoxib inhibits the growth of meningioma xenograft tumors. A. lOMM-Lee 
flank tumors show a dose-dependent growth inhibition with increasing doses of 
celecoxib. Control mice were fed regular mouse chow. Treated mice were fed low-, 
medium-, or high-dose celecoxib diets (500, 1000, and 1500 ppm, respectively). No 
statistically significant difference was found between the control and low (aANOVA,
P>0.05)- or medium (bANOVA, P>0.05)-dose celecoxib treatment groups, whereas a 
statistically significant difference between the control and high-dose celecoxib groups 
was noted by day 43 (cANOVA, P<0.05). Error bars represent 20, 10, 10, and 15 mice 
for the control, low-, medium-, and high-celecoxib groups, respectively. B. CH157-MN
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flank tumors treated with control and high-dose celecoxib. Error bars represent 10 and 5 
mice, respectively. No statistical difference was noted between groups (dANOVA, 
P>0.05). C. Benign meningioma from operative specimen treated with control or high- 
dose celecoxib. A statistical difference was noted between groups by day 43 (eANOVA, 
P<0.05). Error bars represent 5 mice.
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Figure 3. Celecoxib serum levels in animals fed low-, medium-, and high-dose celecoxib 
(500, 1000, and 1500 ppm, respectively) mouse chow ad libitum for a minimum of 35d 
(i.e., drug levels reflect steady state). Mean celecoxib plasma values (±SD) for low-, 
medium-, and high-dose celecoxib are 845(±267), 1540(±493), and 2869(±828)ng/ml_, 
respectively.
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Figure 4: A-C: Bar graphs showing the number of MIB-1 positive cells (A), Factor VIII 
microvascular staining (B), and the number of TUNEL positive cells (C) in meningiomas 
grown in the mouse xenograft flank model for mice fed either regular mouse chow or 
high-dose (1500 ppm) celecoxib chow ad libitum. A. Proliferative rates for the IOMM- 
Lee and CH157-MN tumors showed a slight increase in proliferative cells when treated 
with celecoxib, whereas the benign flank tumors showed a statistically significant 
decrease in the number of MIB-1 positive cells when compared with the control (t-test,
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*P=0.024). B. Microvascular analysis of treated flank tumors showed a decrease in 
microvascular density when compared with control tumors, with statistical difference 
found in the CH157-MN {t-test, *P=0.009J and the benign flank tumors (t-test,
*P= 0.015! C. TUNEL assay of treated groups showed an apparent increase in the 
number of cells undergoing apoptosis, with statistical significance reached in the CH- 
157 and benign flank tumors {t-test, *P=0.002 and *P=0.022, respectively).
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Figure 5: A. Representative pictures of COX-2 and VEGF immunohistochemical staining 
of lOMM-Lee xenograft tumors fed low-, medium-, and high-dose celecoxib (500, 1000, 
and 1500 ppm, respectively) mouse chow ad libitum for 43d. Magnification is 200X. 
Decreased COX-2 and VEGF staining intensity was noted as celecoxib dose increased. 
Arrows identify internal positive controls; both COX-2 and VEGF stain vascular
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endothelium. B-C. Weighted index of COX-2 (B) and VEGF (C) staining showing a 
decrease in score with increasing celecoxib dose. Statistical significance achieved for 
both COX-2 and VEGF (ANOVA, *P<0.001).
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